Congress never intended for safety-net health care providers to make money by buying prescriptions drugs at a discount through the 340B program and billing payers at above the drugs’ acquisition cost, drug manufacturer AstraZeneca (AZN) told a federal district court last week.
When lawmakers created 340B in 1992, they did not want 340B covered entities “to fund themselves through unlimited drug-price arbitrage,” the multinational drug company said. “The idea was to enable grant recipients to acquire drugs cheaply for their poor and uninsured patients, not to generate profits.”
Congress never intended for safety-net health care providers to make money by buying prescriptions drugs at a discount through the 340B program and billing payers at above the drugs’ acquisition cost, drug manufacturer AstraZeneca (AZN) told a federal district court last week.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
